[ad_1]
Three key concerns from investors have been weighing on Charles Schwab Corp. as the brokerage giant’s stock slide extends into a fifth day, JPMorgan Chase analyst Kenneth Worthington said Thursday.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...